Edwards Lifesciences (EW) Cash from Investing Activities (2009 - 2026)

Edwards Lifesciences has reported Cash from Investing Activities for 18 years, with the latest figure at -$193.2 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities fell 12.26% year-over-year to -$193.2 million in Q2 2026; TTM through Jun 2026 was -$912.1 million, a 144.75% decrease from a year earlier, with the FY2025 full-year figure at -$712.9 million, down 130.82% from the prior year.
• Cash from Investing Activities was -$193.2 million for Q2 2026 at Edwards Lifesciences, down from -$92.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $2.7 billion in Q3 2024, with the low at -$576.7 million in Q4 2024.
• Average Cash from Investing Activities over 5 years is $96.7 million, with a median of $38.6 million recorded in 2023.
• The largest YoY upside for Cash from Investing Activities was 12520.0% in 2024 against a maximum downside of 4190.07% in 2024.
• Over 5 years, Cash from Investing Activities stood at $94.7 million in 2022, then slumped by 85.11% to $14.1 million in 2023, then plunged by 4190.07% to -$576.7 million in 2024, then soared by 65.61% to -$198.3 million in 2025, then rose by 2.57% to -$193.2 million in 2026.
• The last three Cash from Investing Activities figures came in at -$193.2 million (Q2 2026), -$92.8 million (Q1 2026), and -$198.3 million (Q4 2025), per Business Quant data.